GLP-1 Drugs Linked to 10% Fewer ER Visits in Chronic Migraine Patients vs. Topiramate
GLP-1 receptor agonists - the drug class that includes semaglutide and liraglutide - were developed for type 2 diabetes and obesity. Over the past several years, researchers have been cataloging a range of effects beyond blood sugar and weight, including signals in cardiovascular health, kidney function, and now, based on a new set of data, migraine burden.
A preliminary study to be presented at the American Academy of Neurology's 78th Annual Meeting compared health outcomes in roughly 11,000 people with chronic migraine who started GLP-1 drugs for another condition - primarily diabetes or weight loss - against 11,000 people with chronic migraine who started topiramate, the most commonly prescribed preventive migraine medication. The comparison was adjusted for age, body mass index, other health conditions, and prior migraine treatment history.
The Numbers from the Health Records Analysis
Over the following year, 23.7% of people starting GLP-1 drugs visited the emergency department, compared with 26.4% of those starting topiramate - approximately a 10% relative reduction. The GLP-1 group was about 14% less likely to be hospitalized for any reason and about 13% less likely to undergo nerve block procedures or receive a first triptan prescription.
The GLP-1 group was also less likely to be started on new preventive migraine medications, suggesting their migraine disease was somewhat more stable during the observation period.
The GLP-1 drugs studied included liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, and albiglutide - capturing the range of agents in clinical use.
"People with chronic migraine often end up in the emergency room or they need to try several preventive medications before finding one that can work for them," said study author Vitoria Acar, MD, of the University of Sao Paulo in Brazil. "Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven't fully appreciated yet."
What the Study Cannot Establish
The study is observational and explicitly does not prove that GLP-1 drugs reduce migraine burden. The comparison group - topiramate initiators - may not be perfectly matched. People prescribed topiramate for migraine prevention are, by definition, patients whose physicians considered them to need preventive therapy, which could reflect a higher baseline disease burden than the GLP-1 group, whose primary indication was metabolic rather than neurological.
Chronic migraine, defined as headache on 15 or more days per month for at least three months with at least eight of those days meeting migraine criteria, affects a significant percentage of migraine patients and is associated with substantial disability. Identifying additional tools to reduce attack frequency and emergency care dependency would have meaningful clinical value - but that identification requires prospective randomized trial data, which this analysis cannot provide.
The study will be presented at the American Academy of Neurology's Annual Meeting taking place April 18-22, 2026, in Chicago and online. It has not yet been published in a peer-reviewed journal.